Part, Chapter, Paragraph
1 II, 5. 12. 5| 2005). In the absence of a vaccine, the control of HCV has
2 II, 6.Acr | Multi-Drug Resistance~MMR vaccine~Measles, Mumps and Rubella
3 II, 6.Acr | Measles, Mumps and Rubella Vaccine~MRSA~Methycillin-Resistant
4 II, 6. 3. 3| introduction in 2006 of a vaccine, but is not a reportable
5 II, 6. 3. 3| have included hepatitis B vaccine in their national vaccination
6 II, 6. 3. 3| virus (HCV), for which no vaccine is available. Up to 90%
7 II, 6. 3. 4| H3N2, and similar to the vaccine strain for the season. Influenza
8 II, 6. 3. 4| European countries but this vaccine is currently underused in
9 II, 6. 3. 4| reduces this risk. The BCG vaccine may be effective in limiting
10 II, 6. 3. 4| high-risk groups. Since the vaccine is not without adverse effects,
11 II, 6. 3. 5| diseases covered by the MMR vaccine (measles, mumps and rubella),
12 II, 6. 3. 5| recent years), even though vaccine coverage is not uniform,
13 II, 6. 3. 5| that have introduced this vaccine. For pertussis, the picture
14 II, 6. 3. 5| from previously attained vaccine coverage levels. Political
15 II, 6. 3. 5| but with over 95% measles vaccine coverage; most of these
16 II, 6. 3. 5| Figure 6.5. Measles (MCV1) vaccine coverage.~ ~
17 II, 6. 3. 5| Conjugated pneumococcal vaccine was registered in the EU
18 II, 6. 3. 5| introduced it as a universal vaccine in their childhood vaccination
19 II, 6. 3. 5| children at-risk. As the vaccine does not cover all serotypes
20 II, 6. 3. 5| using a new conjugated vaccine, but to date there is no
21 II, 6. 3. 5| but to date there is no vaccine against serogroup B disease.~ ~
22 II, 6. 3. 5| introduction of the meningococcal C vaccine in high-risk populations.
23 II, 6. 3. 5| the introduction of the vaccine. In 2005, a total of 5 494
24 II, 6. 3. 5| pertussis. There is an effective vaccine for this disease.~In the
25 II, 6. 3. 5| known to be preventable by vaccine, still affects several European
26 II, 6. 3. 5| humans. There is an effective vaccine available.~ ~An overall
27 II, 6. 3. 5| disease is preventable by a vaccine that provides life-long
28 II, 6. 3. 5| Mumps is preventable by a vaccine.~ ~Between 1996 and 2005,
29 II, 6. 3. 5| reflect a variation in the vaccine coverage by sex (some vaccination
30 II, 6. 3. 5| are changing from the live vaccine to inactivated vaccines
31 II, 6. 3. 5| vaccines in order to avoid vaccine associated flaccid paralysis.~ ~
32 II, 6. 3. 6| surveillance. The available vaccine for S typhi is used mostly
33 II, 6. 3. 6| countries. An effective vaccine is available but it is recommended
34 II, 6. 3. 6| recent years. The available vaccine is used mostly for travellers
35 II, 6. 3. 6| described. A very effective vaccine is available. Almost 210
36 II, 6. 3. 7| has not been documented. A vaccine is available to protect
37 II, 6. 3. 7| occupational risk is required. Vaccine is limited to occupational,
38 II, 6. 3. 7| Europe. No treatment or vaccine is currently available,
39 II, 6. 3. 7| no specific treatment or vaccine available, and up to 30%
40 II, 6. 3. 7| fluids. No treatment or vaccine is available for either
41 II, 6. 3. 7| administration of a highly effective vaccine.~ ~Yellow fever has not
42 II, 9. 2. 3| particularly those categorised as ‘vaccine preventable’. However, with
43 II, 9. 2. 3| what can be considered ‘vaccine preventable’ is not static,
44 II, 9. 2. 3| measles, mumps and rubella) vaccine. The apparent scientific
45 II, 9. 2. 3| of measles-mumps-rubella vaccine during childhood means that
46 II, 9. 3. 1| infection with genital warts. A vaccine for HPV has become recently
47 III, 10. 3. 3| countries. An effective vaccine is available but it is recommended
48 IV, 12. 2 | to the development of a vaccine against the Human Papilloma
49 IV, 12. 10 | authorised establishments. The vaccine against the human papilloma
